Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 26, 2017
Pharmacy Choice - News - Pharmaceutical Development - May 26, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/26/17 - Abbott Labs: A genomic disease management company, engages in the development and marketing of clinical laboratory products, which provide information critical to the evaluation and management of cancer, prenatal disorders, and other genetic diseases
It currently markets seven U.S. Food and Drug Administration or foreign cleared or approved clinical products in addition to distributing over 300 Analyte Specific Reagent and research products through its direct sales operations in the United States and Europe and a worldwide distribution network covering 59 countries. Mary Szela joined Melinta...
5/26/17 - Abeona Therapeutics receives FDA orphan designation for gene therapy
The FDA has granted Orphan Drug Designation for Abeona Therapeutics's EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa...
5/26/17 - Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa [Tehran Times (Iran)]
Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the FDA has granted Orphan Drug Designation for Abeonas EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa, including recessive dystrophic...
5/26/17 - Active Pharmaceutical Ingredients Market Outlook and Worldwide Forecast to 2027
Global Active Pharmaceutical Ingredients Information, by types, by applications, by manufacturing method-Forecast 2027 Pune, India 05/26/2017 Market Synopsis of Active pharmaceutical ingredients Market:. Active Pharmaceutical Ingredient is the integral part of the drug because of which the disease gets cured. Request a Sample Report@...
5/26/17 - Advanced Accelerator Applications (AAAP) Appoints Christine Mikail to Board of Directors [National News Agency (Lebanon)]
Advanced Accelerator Applications S.A. today announced that Christine Mikail, J.D. has joined the Companys board of directors as an independent non-executive director. Ms. Mikail brings both a broad legal skillset and substantial business development experience in the pharmaceutical industry, stated Stefano Buono, Chief Executive Officer of AAA.
5/26/17 - AERI Is Awesome, GWPH Abuzz, FDA Panel Nod For PBYI [Sport360]
Today`s Daily Dose brings you news about Aerie Pharma`s positive efficacy results from phase III study of its glaucoma drug candidate Roclatan; Alnylam`s public offering and FDA panel`s support for approval of Puma`s breast cancer drug Neratinib. Shares of Aerie Pharmaceuticals Inc. climbed more than 27% in extended trading on Wednesday, following.
5/26/17 - Agency Information Collection Activities: Proposed Collection; Comment Request; Applications for Food and Drug Administration Approval To Market a...
SUMMARY: The Food and Drug Administration is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed...
5/26/17 - American Discount Pharmacy Corp./ UPS: Has been featured on Fox and Wink TV for having some of the best prices on FDA-approved and USA Wholesaler medications
American Discount Pharmacy Corp./ UPS. American Discount Pharmacy has been featured on Fox and Wink TV for having some of the best prices on FDA- approved and USA Wholesaler medications. Their is a prototype UPS located within the store of American Discount Pharmacy Corp./ UPS and we are proud to be a part of this unique combination.
5/26/17 - Apellis Receives EMA Orphan Drug Designation for APL-2 in PNH
By a News Reporter-Staff News Editor at Drug Week Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, announced that the European Medicines Agency has granted orphan medicinal product designation to APL-2, a complement C3 inhibitor, in the treatment of patients with paroxysmal.
5/26/17 - Araim Pharmaceuticals' Cibinetide ARA 290 Regenerates Small Nerve Fibers and Improves Neuropathic Clinical Symptoms in the Orphan Disease of...
Araim Pharmaceuticals' Cibinetide ARA 290 Regenerates Small Nerve Fibers and Improves Neuropathic Clinical Symptoms in the Orphan Disease of Sarcoidosis. By a News Reporter-Staff News Editor at Health& Medicine Week Araim Pharmaceuticals Inc., announced the publication of Phase 2 b study results in small fiber neuropathy of the Company's lead com
5/26/17 - Autism study questions and answers [The San Diego Union-Tribune]
May 26 This question and answer article about the autism clinical trial led by Robert Naviaux, professor of genetics in the departments of medicine, pediatrics and pathology of the University of California San Diego, was provided by the university. It describes the rationale for using the old sleeping sickness drug suramin and implications if the
5/26/17 - Autism symptoms improve in small clinical trial of century-old drug [The San Diego Union-Tribune]
May 26 Autism symptoms improved in five boys given a century-old drug for sleeping sickness, according to a new study led by University of California San Diego researchers. The small clinical trial involved 10 boys, including five who received a placebo and did not show improvement. The gains lasted for several weeks, said Robert Naviaux, a UC Sa
5/26/17 - Autism symptoms of five boys improve in early trial of century-old drug [The San Diego Union-Tribune]
May 26 Autism symptoms improved in five boys given a century-old drug for sleeping sickness, according to a new study led by University of California San Diego researchers. The small clinical trial involved 10 boys, including five who received a placebo and did not show improvement. The gains lasted for several weeks, said Robert Naviaux, a UC Sa
5/26/17 - Avastin as effective as Eylea for treating central retinal vein occlusion
By a News Reporter-Staff News Editor at Health& Medicine Week Monthly eye injections of Avastin are as effective as the more expensive drug Eylea for the treatment of central retinal vein occlusion, according to a clinical trial funded by the National Eye Institute, part of the National Institutes of Health. "This head-to-head comparison of two
5/26/17 - Bioblast Pharma Reports First Quarter 2017 Financial Results
R&D Expenses: Research and development expenses were $1.1 million for the quarter ended March 31, 2017, compared to $1.9 million for the same period in 2016. The decrease was primarily related to reduced clinical trial related activities, specifically as our planned Phase 2 b clinical study in Ocular Pharyngeal Muscular Dystrophy patients has not y
5/26/17 - BioPharma Services, Inc. Successfully Completes 3 FDA Inspections with ZERO Form 483's
BioPharma Services, Inc. is proud to announce that it has successfully completed 3 inspections this month by the US FDA, with concurrent audits at both research centers in Toronto, Canada, and Columbia, Missouri. Over the course of 2 weeks, the back-to-back inspections focused on a total of 9 studies including 4 bioanalytical validations that were
5/26/17 - Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk
Release date- 23052017- AstraZeneca today announced top-line results from the Phase IIIb/IV EXSCEL trial. These results address the US Food and Drug Administration requirement that medicines to treat T2D are not associated with an increase in CV risk. Elisabeth Bjork, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines..
5/26/17 - Company Profile for Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. One of the world s leading, full-service contract research organizations, we partner with sponsors in the pharmaceutical and biotechnology industries to deliver fully integrated c
5/26/17 - Data from M.R. Geier et al Provide New Insights into Vaccines [Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a...
Data from M.R. Geier et al Provide New Insights into Vaccines. According to news originating from Silver Spring, Maryland, by NewsRx correspondents, research stated, "Gardasil is a quadrivalent human papillomavirus vaccine that was approved for use by the US Food and Drug Administration in June 2006. HPV4 vaccine is routinely recommended for admini
5/26/17 - Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Endocyte, Inc., a leader in developing targeted small molecule drug conjugates and companion imaging agents for personalized therapy, today announced that two posters will be presented on its lead, clinical-stage assets, EC1456 and EC1169, at the 2017 American Society of Clinical Oncology Annual Meeting being held June 2- 6, 2017, in Chicago..
5/26/17 - EU regulators widen approval for Zebinix [Syrian Arab News Agency]
The European Medicines Agency has cleared use of Bial and Eisais sodium channel blocker Zebinix for use as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy, widening its treatment scope in the region. Zebinix is already indicated in Europe as adjunctive therapy in adults, adolescents and children aged above six y
5/26/17 - FDA approves Sun Pharmas tildrakizumab for moderate-to-severe plaque psoriasis [Sudan Tribune]
Indian company Sun Pharmaceutical Industries has received the US Food and Drug Administration approval of the Biologics License Application for tildrakizumab to treat patients with moderate-to-severe plaque psoriasis. The FDA filing acceptance follows acceptance of the regulatory filing of tildrakizumab by the European Medicines Agency in March...
5/26/17 - FDA Panel Recommends Approval Of Epoetin Alfa Biosimilar Across All Indications
NEW YORK CITY- Pfizer Inc. said that the United States Food and Drug Administration Oncologic Drugs Advisory Committee recommended to approve Company's proposed epoetin alfa biosimilar across all indications. This marks the first time a biosimilar erythropoiesis-stimulating agent has been recommended for approval by a U.S. FDA Advisory Committee.
5/26/17 - First of Its Kind Clinical Trial for Children With DIPG to Make Data Available in the Cloud
Dragon Master Foundation has announced plans to provide $300,000 in funding for the first clinical trial that will make patient data available live in the cloud while the trial is underway. The clinical trial is an initiative by the Pacific Pediatric Neuro-Oncology Consortium in partnership with the Children's Brain Tumor Tissue Consortium to...
5/26/17 - Glenmark Pharmaceuticals gets ANDA approval for Olmesartan Medoxomil Tablets [India Infoline News Service]
Glenmark Pharmaceuticals on Friday informed that it has received ANDA approval by the United States Food& Drug Administration for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg, as per BSE filing. Glenmark Pharmaceuticals on Friday informed that it has received ANDA approval by the United States Food& Drug Administration for Olmesartan Medoxom
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415